신경교육종 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.3%로 성장할 전망이며, 15억 4,000만 달러로 성장이 예측됩니다. 예측 기간 성장의 원동력은 신경교육종 이환율 증가, 뇌종양에 대한 의식 증가, 뇌종양에 대한 연구자금 증가, 맞춤형 치료에 대한 수요 증가, 헬스케어 인프라 확대로 예측됩니다. 주요 동향은 진단 기술의 발전, 표적 요법 개발, 고급 영상 기술의 가용성, 수술 기술의 혁신, 약물 전달 시스템의 기술적 진보 등을 포함합니다.
뇌종양의 이환율 증가는 신경교육종 시장의 성장을 가속할 것으로 예측됩니다. 뇌종양은 뇌 내 세포의 비정상적인 증식으로 양성 또는 악성일 수 있으며, 두통, 발작, 시력 장애와 같은 증상을 유발할 수 있습니다. 뇌종양의 증례 수가 증가하고 있는 것은 진단 기술의 향상, 의식 고조, 위험 인자에 노출되기 쉬운 환경 및 생활 습관의 요인에 의한 것입니다. 신경교육종 치료는 이 공격적이고 희귀한 암을 관리하는데 중요한 역할을 하며, 증상의 완화, 생존 기간의 연장, 환자의 QOL의 향상을 목표로 하고 있습니다. 예를 들어, 2022년 10월 미국 연방 정부가 운영하는 미국 생물의학 도서관인 국립의학 도서관은 2023년 미국에서는 뇌 및 중추신경계(CNS) 종양의 신규 사례가 94,390례 기록되었으며, 2022년 93,470례에서 증가했다고 보고했습니다. 악성 사례는 26,670례에서 26,940례로 증가하였고, 비악성 사례는 66,800례에서 67,440례로 증가했습니다. 이와 같이 뇌종양의 이환율 증가는 신경교육종 치료에 대한 수요를 촉진하고 있습니다.
신경교육종 시장의 주요 기업은 암 치료와 모니터링을 강화하기 위한 고급 웨어러블 기술의 개발에 주력하고 있습니다. 웨어러블 디바이스는 건강 데이터를 추적하고 분석하여 실시간 인사이트를 제공하고 환자 인게이지먼트를 향상시키는 신체에 장착하는 전자 장치입니다. 예를 들면, 2024년 11월, 영국을 거점으로 하는 온콜로지 기업인 Novocure Ltd.는, 다형교모종(GBM)의 성인 환자를 치료하기 위해서, Optune Gio와 함께 Head Flexible Electrode(HFE) 트랜스듀서 어레이의 사용에 대해 미국 식품의약국(FDA)의 승인을 취득했습니다. Optune Gio는 비침습적 어레이를 사용하여 종양 치료 자기장(TT Fields)을 조사하는 휴대용 웨어러블 장치로, 이 자기장은 분열 중 암세포의 대전 성분에 물리적 힘을 가해 그 급속한 증식을 저해합니다. 새롭게 도입된 HFE 어레이는 기존 Optune Gio 어레이에서 사용되는 세라믹 디스크보다 50% 얇고 3분의 1 경량이며 유연한 폴리머 소재로 만들어져 환자의 편안함과 사용 편의성이 향상되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 신경교육종 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 신경교육종 시장 : 성장률 분석
- 세계의 신경교육종 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 신경교육종 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 신경교육종 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 신경교육종 시장 : 진단 방법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 화상 기술
- 조직병리학적 검사
- 바이오마커 검사
- 세계의 신경교육종 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 수술
- 방사선치료
- 화학요법
- 표적요법
- 면역요법
- 세계의 신경교육종 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 암 연구기관
- 전문 클리닉
- 세계의 신경교육종 시장 : 화상 기술 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 자기 공명 영상법(MRI)
- 컴퓨터 단층 촬영(CT) 스캔
- 양전자 방출 단층 촬영(PET) 스캔
- 세계의 신경교육종 시장 : 조직 병리학적 검사별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 헤마톡실린 에오신(H&E) 염색
- 면역조직화학(IHC)
- 전자현미경
- 세계의 신경교육종 시장 : 바이오마커 검사 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- IDH 돌연변이 검사
- MGMT 프로모터 메틸화 시험
- ATRX 돌연변이 검사
- TP53 돌연변이 해석
제7장 지역별 및 국가별 분석
- 세계의 신경교육종 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 신경교육종 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 신경교육종 시장 : 경쟁 구도
- 신경교육종 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd.
- Sumitomo Dainippon Pharma
- Bio-Rad Laboratories Inc.
- Carl Zeiss AG
- Elekta AB
- Novocure Ltd.
- ImmunityBio Inc.
- Immatics Biotechnologies
- Karyopharm Therapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 신경교육종 시장(2029년) : 새로운 기회를 제공하는 국가
- 신경교육종 시장(2029년) : 새로운 기회를 제공하는 부문
- 신경교육종 시장(2029년) : 성장 전략
제36장 부록
AJY
Gliosarcoma is a rare and aggressive brain tumor composed of both glial and sarcomatous tissue, primarily occurring in the cerebral hemisphere. It is studied to understand tumor biology and develop treatment strategies for glioblastoma and other brain malignancies.
The primary diagnostic methods for gliosarcoma include imaging techniques, histopathological examination, and biomarker testing. Imaging techniques, such as MRI, CT, and PET scans, are non-invasive methods used to visualize internal structures and detect abnormalities. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with end users including hospitals, cancer research institutes, and specialty clinics.
The gliosarcoma market research report is one of a series of new reports from The Business Research Company that provides gliosarcoma market statistics, including gliosarcoma industry global market size, regional shares, competitors with a gliosarcoma market share, detailed gliosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the gliosarcoma industry. This gliosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gliosarcoma market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period was driven by increasing healthcare expenditure, a rising number of clinical trials, a growing global aging population, a higher prevalence of comorbidities such as diabetes and hypertension, and expanded healthcare insurance coverage.
The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period is expected to be driven by the increasing incidence of gliosarcoma, rising awareness of brain cancers, growth in research funding for brain cancer, increasing demand for personalized treatments, and the expansion of healthcare infrastructure. Key trends include advancements in diagnostic techniques, the development of targeted therapies, the availability of advanced imaging technologies, innovations in surgical techniques, and technological advancements in drug delivery systems.
The rising incidence of brain tumors is expected to drive growth in the gliosarcoma market. A brain tumor is an abnormal growth of cells in the brain, which can be either benign or malignant and may cause symptoms such as headaches, seizures, and vision problems. The increasing number of brain tumor cases is attributed to improved diagnostic technologies, heightened awareness, and environmental and lifestyle factors that may contribute to greater exposure to risk factors. Gliosarcoma treatment plays a crucial role in managing this aggressive and rare cancer, aiming to alleviate symptoms, extend survival, and enhance the patient's quality of life. For example, in October 2022, the National Library of Medicine, a US-based biomedical library operated by the United States federal government, reported that in 2023, the United States recorded 94,390 new cases of brain and central nervous system (CNS) tumors, up from 93,470 cases in 2022. Malignant cases increased from 26,670 to 26,940, while non-malignant cases rose from 66,800 to 67,440. The growing incidence of brain tumors is thus fueling demand for gliosarcoma treatment.
Leading companies in the gliosarcoma market are focusing on developing advanced wearable technology to enhance cancer treatment and monitoring. Wearable devices are electronic gadgets worn on the body that track and analyze health data, offering real-time insights and improving patient engagement. For instance, in November 2024, Novocure Ltd., a UK-based oncology company, received U.S. Food and Drug Administration (FDA) approval for the use of Head Flexible Electrode (HFE) transducer arrays alongside Optune Gio for treating adult patients with glioblastoma multiforme (GBM). Optune Gio is a portable, wearable device that uses non-invasive arrays to deliver tumor-treating fields (TTFields), which apply physical forces to electrically charged components of dividing cancer cells, disrupting their rapid growth. The newly introduced HFE arrays are 50% thinner and one-third lighter than the ceramic discs used in the existing Optune Gio arrays, as they are made from a flexible polymer material, enhancing patient comfort and usability.
In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences in a $1.3 billion deal. This acquisition strengthens Merck's oncology portfolio by advancing innovative therapies for glioblastoma and other cancers, further expanding its expertise in cancer treatment. Modifi Biosciences, based in the U.S., specializes in developing treatments for glioblastoma, reinforcing Merck's commitment to addressing complex oncological challenges.
Major players in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., Komipharm International Co. Ltd., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.
North America was the largest region in the gliosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gliosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gliosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gliosarcoma market consists of revenues earned by entities by providing services such as molecular diagnostics, clinical trials and research, palliative care services, rehabilitation, and recovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gliosarcoma market also includes sales of diagnostic kits, research reagents, and patient monitoring devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gliosarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gliosarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gliosarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gliosarcoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Diagnosis Method: Imaging Techniques; Histopathological Examination; Biomarker Testing
- 2) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy
- 3) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics
- Subsegments:
- 1) By Imaging Techniques: Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan; Positron Emission Tomography (PET) Scan
- 2) By Histopathological Examination: Hematoxylin and Eosin (H&E) Staining; Immunohistochemistry (IHC); Electron Microscopy
- 3) By Biomarker Testing: IDH Mutation Testing; MGMT Promoter Methylation Testing; ATRX Mutation Testing; TP53 Mutation Analysis
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gliosarcoma Market Characteristics
3. Gliosarcoma Market Trends And Strategies
4. Gliosarcoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Gliosarcoma Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gliosarcoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gliosarcoma Market Growth Rate Analysis
- 5.4. Global Gliosarcoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gliosarcoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gliosarcoma Total Addressable Market (TAM)
6. Gliosarcoma Market Segmentation
- 6.1. Global Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Imaging Techniques
- Histopathological Examination
- Biomarker Testing
- 6.2. Global Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- 6.3. Global Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Research Institutes
- Specialty Clinics
- 6.4. Global Gliosarcoma Market, Sub-Segmentation Of Imaging Techniques, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT) Scan
- Positron Emission Tomography (PET) Scan
- 6.5. Global Gliosarcoma Market, Sub-Segmentation Of Histopathological Examination, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hematoxylin and Eosin (H&E) Staining
- Immunohistochemistry (IHC)
- Electron Microscopy
- 6.6. Global Gliosarcoma Market, Sub-Segmentation Of Biomarker Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- IDH Mutation Testing
- MGMT Promoter Methylation Testing
- ATRX Mutation Testing
- TP53 Mutation Analysis
7. Gliosarcoma Market Regional And Country Analysis
- 7.1. Global Gliosarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gliosarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gliosarcoma Market
- 8.1. Asia-Pacific Gliosarcoma Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gliosarcoma Market
- 9.1. China Gliosarcoma Market Overview
- 9.2. China Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gliosarcoma Market
- 10.1. India Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gliosarcoma Market
- 11.1. Japan Gliosarcoma Market Overview
- 11.2. Japan Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gliosarcoma Market
- 12.1. Australia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gliosarcoma Market
- 13.1. Indonesia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gliosarcoma Market
- 14.1. South Korea Gliosarcoma Market Overview
- 14.2. South Korea Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gliosarcoma Market
- 15.1. Western Europe Gliosarcoma Market Overview
- 15.2. Western Europe Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gliosarcoma Market
- 16.1. UK Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gliosarcoma Market
- 17.1. Germany Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gliosarcoma Market
- 18.1. France Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gliosarcoma Market
- 19.1. Italy Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gliosarcoma Market
- 20.1. Spain Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gliosarcoma Market
- 21.1. Eastern Europe Gliosarcoma Market Overview
- 21.2. Eastern Europe Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gliosarcoma Market
- 22.1. Russia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gliosarcoma Market
- 23.1. North America Gliosarcoma Market Overview
- 23.2. North America Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gliosarcoma Market
- 24.1. USA Gliosarcoma Market Overview
- 24.2. USA Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gliosarcoma Market
- 25.1. Canada Gliosarcoma Market Overview
- 25.2. Canada Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gliosarcoma Market
- 26.1. South America Gliosarcoma Market Overview
- 26.2. South America Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gliosarcoma Market
- 27.1. Brazil Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gliosarcoma Market
- 28.1. Middle East Gliosarcoma Market Overview
- 28.2. Middle East Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gliosarcoma Market
- 29.1. Africa Gliosarcoma Market Overview
- 29.2. Africa Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gliosarcoma Market Competitive Landscape And Company Profiles
- 30.1. Gliosarcoma Market Competitive Landscape
- 30.2. Gliosarcoma Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Gliosarcoma Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb Company
- 31.2. Novartis AG
- 31.3. Eli Lilly and Company
- 31.4. Amgen Inc.
- 31.5. Teva Pharmaceutical Industries Ltd.
- 31.6. Regeneron Pharmaceuticals Inc.
- 31.7. Sun Pharmaceutical Industries Ltd.
- 31.8. Sumitomo Dainippon Pharma
- 31.9. Bio-Rad Laboratories Inc.
- 31.10. Carl Zeiss AG
- 31.11. Elekta AB
- 31.12. Novocure Ltd.
- 31.13. ImmunityBio Inc.
- 31.14. Immatics Biotechnologies
- 31.15. Karyopharm Therapeutics Inc.
32. Global Gliosarcoma Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gliosarcoma Market
34. Recent Developments In The Gliosarcoma Market
35. Gliosarcoma Market High Potential Countries, Segments and Strategies
- 35.1 Gliosarcoma Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gliosarcoma Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gliosarcoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
